MINNEAPOLIS, July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT to review fourth quarter and fiscal 2024 financial results.
Access to the discussion may be obtained as follows:
Time: | 8:00 a.m. CDT |
Date: | August 7, 2024 |
Dial-in: | 1-800-343-4136 or 1-203-518-9843 (for international callers) |
Conference ID: | BioTechne |
Webcast: |
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11156560.
The replay will be available from 11:00 a.m. CDT on Wednesday, August 7, 2024, until 11:00 p.m. CDT on Saturday, September 7, 2024.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
612-656-4416
| Last Trade: | US$75.38 |
| Daily Change: | 0.51 0.68 |
| Daily Volume: | 538,380 |
| Market Cap: | US$11.960B |
November 27, 2024 November 25, 2024 November 18, 2024 November 14, 2024 November 11, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
